Esperion Therapeutics Files 8-K

Ticker: ESPR · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1434868

Esperion Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyEsperion Therapeutics, Inc. (ESPR)
Form Type8-K
Filed DateOct 7, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: reporting, corporate-filing

TL;DR

Esperion filed a standard 8-K, no major news.

AI Summary

Esperion Therapeutics, Inc. filed an 8-K on October 7, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial details or new material events beyond the standard reporting requirements for this form type. The company is incorporated in Delaware and headquartered in Ann Arbor, Michigan.

Why It Matters

This 8-K filing indicates routine corporate reporting by Esperion Therapeutics, Inc. It does not appear to disclose any new material events or financial updates that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K with no new material information disclosed, indicating low immediate risk.

Key Numbers

  • 001-35986 — SEC File Number (Esperion's SEC filing identifier)
  • 26-1870780 — IRS Employer Identification No. (Esperion's tax identification number)

Key Players & Entities

  • Esperion Therapeutics, Inc. (company) — Registrant
  • October 7, 2025 (date) — Date of Earliest Event Reported
  • Delaware (jurisdiction) — State of incorporation
  • Ann Arbor, MI (location) — Principal executive offices
  • HDL THERAPEUTICS INC (company) — Former company name

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of October 7, 2025.

When was Esperion Therapeutics, Inc. incorporated?

Esperion Therapeutics, Inc. is incorporated in Delaware.

What is Esperion Therapeutics, Inc.'s principal executive office address?

Esperion Therapeutics, Inc.'s principal executive office is located at 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108.

Does this filing indicate any significant new business developments?

Based on the provided information, this 8-K filing appears to be a routine report and does not explicitly disclose any significant new business developments or material events.

What was Esperion Therapeutics, Inc.'s former company name?

Esperion Therapeutics, Inc.'s former company name was HDL THERAPEUTICS INC.

Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-10-07 16:08:39

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market

Filing Documents

01. Other Events

Item 8.01. Other Events. On October 7, 2025, Esperion Therapeutics, Inc. (the "Company") posted an updated corporate presentation to its website at https://www.esperion.com/investors-media. A copy of the updated corporate presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Reference to the Company's website is for inactive textual reference only and the content of the website should not be deemed incorporated by reference into this Current Report on Form 8-K

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation dated October 2025. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 7, 2025 Esperion Therapeutics, Inc. By: /s/ Sheldon L. Koenig Sheldon L. Koenig President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.